Author:adminTime:2019/12/5 21:22:33Click:1874
March 4, 2019 / BIOON /-Biocor Therapeutics has announced the launch of Inbrija (levodopa inhalation powder) in the US market. The drug was approved by the US FDA on December 21, 2018 for use in Intermittent treatment for patients with Parkinson's di····
Author:adminTime:2019/12/5 21:19:23Click:1731
Oyster Point Pharmaceuticals has submitted a NASDAQ listing application to the US Securities and Exchange Commission, and plans to raise $ 85 million in an IPO. This is a biotechnology company dedicated to developing first-in-class therapies for dry ····
Author:adminTime:2019/12/5 21:15:38Click:1881
October 10, 2019 / Bio Valley BIOON /-Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, recently announced that it has submitted a new supplement to the US Food and Drug Administration (FDA) depression drug Spravato (esketamine) CIII nasal spr····
Author:adminTime:2019/12/5 21:14:04Click:1880
On March 5, local time, the FDA issued a statement saying it agreed to approve the launch of a new nasal spray drug, Spravato (Esketamine), for the treatment of resistant depression. This is the first major depression treatment to enter the US market····
Author:adminTime:2019/11/28 9:52:07Click:1793
Belgian pharmaceutical company UCB recently announced that the US FDA has approved its latest antiepileptic drug (AED) Nayzilam (midazolam) nasal spray CIV. This is a benzodiazepine drug for nasal administration. It is suitable for the emergency trea····